Indaptus Therapeutics Drops on Cash Runway Worries
Indaptus Therapeutics shares fell 6.6% to $1.14 Tuesday after the company reported $1.5 million in cash at March 31 and raised “substantial doubt” about its ability to continue operating. The company stopped enrolling patients in its main clinical trial and has no approved therapies or product revenue. Indaptus converted all Series AA and AAA preferred shares into 111 million common shares during the quarter.
